What I find hard to fathom is that if he found a reasonable buyer for AMRN
he and the entire management team would benefit the most. If they know
that selling AMRN is the best way to create shareholder value, not to
mention making Vascepa more widely available through an established
distribution network, what would keep them from pursuing such a deal?
Basically, it is common sense and logical that Vascepa would be a much
more successful drug if BP owned it. Let's hope the big institutions
will see it that way as well. Until then, I will perter IR with my
very polite rants to sell the company or replace JT with someone
who can.